SCHEMBL1531726

SCHEMBL1531726

CCCCCCCCCCCCCCCC(=O)OC(CCCCCC)CCCCCCCCCCC(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.64
MAPT P10636 2/20 0.64
FFAR4 Q5NUL3 2/20 0.61
FFAR1 O14842 2/20 0.61
ALDH1A1 P00352 3/20 0.60
LMNA P02545 2/20 0.60
TSHR P16473 5/20 0.59
CYP1A2 P05177 2/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
GMNN O75496 1/20 0.59
HSP90AA1 P07900 1/20 0.59
BLM P54132 1/20 0.59
NPSR1 Q6W5P4 1/20 0.59
NR1H4 Q96RI1 1/20 0.59
TP53 P04637 1/20 0.59
CYP2C9 P11712 1/20 0.59
HIF1A Q16665 1/20 0.59
GPR84 Q9NQS5 7/20 0.59
PPARG P37231 6/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Myristic Acid SCHEMBL9408104 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL215669 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL6843599 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL2154198 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL23288413 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL8656695 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL23860683 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL23565739 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL25297686 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1
SCHEMBL22589987 1.00 MAPK1 (0.64) MAPK1MAPTFFAR4FFAR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734959-A1 USE OF GLYCERIDES FOR LNP FORMULATIONS Sanofi Pasteur Inc. (US) 2026-05-06 EP claimed
WO-2025003754-A1 USE OF GLYCERIDES FOR LNP FORMULATIONS SANOFI (FR) 2025-01-02 WO claimed
CN-117737146-B Glyceride type fatty acid hydroxy fatty acid ester and preparation method thereof 广东省农业科学院蚕业与农产品加工研究所 2024-06-18 CN claimed
CN-117737146-A Glyceride type fatty acid hydroxy fatty acid ester and preparation method thereof 广东省农业科学院蚕业与农产品加工研究所 2024-03-22 CN claimed
EP-4734959-A1 USE OF GLYCERIDES FOR LNP FORMULATIONS Sanofi Pasteur Inc. (US) 2026-05-06 EP disclosed
WO-2026089660-A1 A PLATFORM FOR MIMICKING BIOLOGICAL AIR-INTERFACES NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2026-04-30 WO disclosed
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) 2026-03-10 US disclosed
EP-4688725-A1 FATTY ACID ESTERS OF HYDROXY FATTY ACID Wilmar International Limited (SG) 2026-02-11 EP disclosed
EP-4637812-A1 HEPATITIS B COMPOSITIONS GlaxoSmithKline Biologicals S.A. (BE) 2025-10-29 EP disclosed
EP-4539876-A2 RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 GlaxoSmithKline Biologicals S.A. (BE) 2025-04-23 EP disclosed
US-20250099576-A1 Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2 GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2025-03-27 US disclosed
CN-119604304-A Recombinant RNA molecules comprising an untranslated region or a segment encoding spike protein from the Severe acute respiratory coronavirus 2 Omikovia strain 葛兰素史克生物有限公司 2025-03-11 CN disclosed
US-20100029622-A1 MICROEMULSIONS NEUROSCIENZE PHARMANESS S.C.A.R.L. (IT) 2010-02-04 US disclosed
US-20100028257-A1 PHARMACEUTICAL COMPOUNDS NEUROSCIENZE PHARMANESS S.C. A.R.L. (IT) 2010-02-04 US disclosed
EP-2149575-A1 Diazabicyclic compounds as opioid receptor agonists Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-02-03 EP disclosed
EP-2149370-A1 Diazabicyclic compounds and microemulsions thereof Neuroscienze Pharmaness S.C. A R.L. (IT) 2010-02-03 EP disclosed
US-7491836-B2 Non-ionic surfactants for poorly soluble molecules ASTRAZENECA AB (SE) 2009-02-17 US disclosed
US-20060287542-A1 Non-ionic surfactants for solubilizing poorly solubule molecules ASTRAZENECA AB (SE) 2006-12-21 US disclosed
EP-1615874-A1 NEW NON-IONIC SURFACTANTS FOR SOLUBILIZING POORLY SOLUBLE MOLECULES AstraZeneca AB (SE) 2006-01-18 EP disclosed
WO-2004089869-A1 NEW NON-IONIC SURFACTANTS FOR SOLUBILIZING POORLY SOLUBLE MOLECULES ASTRAZENECA AB (SE) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100028257-A1 PHARMACEUTICAL COMPOUNDS OPRD1, OPRK1, OPRM1 MAPK1 1372/4885MAPT 3497/4885FFAR4 820/4885
US-20250099576-A1 Recombinant RNA Molecules Comprising Untranslated Regions or Segments Encoding Spike Protein from the Omicron Strain of Severe Acute Respiratory Coronavirus-2 RNGTT, RBM25, TMPRSS2 MAPK1 4108/4885MAPT 2648/4885FFAR4 3910/4885
US-20060287542-A1 Non-ionic surfactants for solubilizing poorly solubule molecules LIPA, ELOVL1, FASN MAPK1 3146/4885MAPT 4810/4885FFAR4 137/4885
US-20100029622-A1 MICROEMULSIONS LIPA, APOB, LIPC MAPK1 4060/4885MAPT 77/4885FFAR4 416/4885
US-12569439-B2 Bottom-up assembly of synthetic extracellular vesicles EXOSC10, PLTP, EXOSC9 MAPK1 1783/4885MAPT 2688/4885FFAR4 256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.